Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

The Calandra Report: Blood in streets, rivers of fortune

Thom Calandra Thom Calandra, www.thomcalandra.com
3 Comments| July 24, 2015

{{labelSign}}  Favorites
{{errorMessage}}

See: EXK/EDR, RDE, ATY, ANK, IMV, BCRX


There is blood in the streets. It is my portfolio blood.

A friend of mine says this week, "Everyone in the world says they like to buy when there is blood in the streets, just not when it is their blood."

Or on their streets. I come to drink the blood. Plasma even, when it spills on my paper. My portfolio swings -- and those at our TCR -- are ruby-blood on the way down and celestial on the up.

Here are our latest TCR actionables, starting with a free lunch:

-- Those of our TCR family on Manhattan a week from today | Thursday July 30: the Nevada gold prospector along the Cortez trend that will make all of us wealthy in the short term. Here is the invite.

-- I try to track insider purchases in bad and good times, and not capitulations and stock-chart gazers; thus, Angkor Gold's CEO is buying on average about 5,000 shares a day.

Click to enlarge

-- I'll be tuned into BioCryst Pharma's quarterly conference call for next steps in the southern USA lab's strategy of developing orally taken drugs that treat rare diseases, for influenza and for bio-terrorim agents. The only blood there is in the lab -- as BCRX stock is flying.

-- See this article for fresh news about a secular trend -- profiteering drug-pricing -- that will benefit, yes, benefit longstanding labs with low-priced cancer and immunological solutions. Immunovaccine in Halifax, Canada, is at the top of ourTCR list. That drug-price article, all about blood in the streets, is here. The stock ticker for our low-priced alternative is IMV in Canada, and that stock is making us money, too.

-- I'm down so far on my natural resources, that in this fifth year of bleeding bloody hell, even the devil won't stoop to pitchfork my low-priced holdings. One I know well and personally, Endeavour Silver, is beneath even Hades-level stock-price criteria. Stare at the chart here too long and you turn into a statue of salt. The Mexico producer looks like it will produce about 11 million ounces of silver (silver-equivalent includes gold ounces) in 2015. Endeavour Silver's stock is approaching $1 USD -- which is close to its late-2008 low. I am a buyer: EXK in USA.

-- What else is chewable: Red Eagle Mining and Atico Mining are both in Colombia and are both rising Thursday. Red Eagle has about all the pieces it needs to become that nation's next new gold mine -- within a long bike ride of the city of Medellin. Atico Mining, which I know well and own, produces copper and gold at respectably low prices at El Roble, which is underground and surrounded by what I believe are economic volcanic deposits of more gold and copper. ... I also thinkTiVo shares right here at $10 USD or so are capable of rising twofold or more via fresh streaming-video contracts or an outright change of control to Netflix, Google or one of the cable-media companies in the USA or Britain.

Tickers: ANK (Canada), NUG (Canada), BCRX (USA), IMV (Canada), EXK in USA and EDR in Canada, TIVO in USA, ATY in Canada, RDE in Canada

-- Thom Calandra


THE CALANDRA REPORT: Subscribe
Now $139 yearly!

See: a thomcalandra.com home for our expanding TCR family.


THE CALANDRA REPORT
$139: Will Recur Yearly


Thom Calandra & TCR are researchers and investors. They are not registered investment advisers. The research and material they offer to subscribers are meant as editorial opinion.



{{labelSign}}  Favorites
{{errorMessage}}

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today

Featured Company